Yeasts are unicellular microorganisms that belong to the fungi family. The species Candida albicans is the most common. It accounts for the fourth largest cause of blood infections in hospitals and one that is known to have a 40 percent mortality rate acording to the CDC). Following Candida in prevalence is Aspergillus, Blastomyces, Coccidioides, Histoplasma, Pneumocystis carinii, Cryptococcus neoformans and Trichosporon. These microorganisms are usually contracted by airborne spores and can cause serious infections and death, especially in individuals with compromised immune systems.
Dimorphism, or the ability to exist in two distinct forms, is an important characteristic in pathogenic yeasts. It allows them to change their properties of growth. From simple fission or budding, pathogenic yeasts begin to grow hyphae that elongate their structure into rows of cells allowing for penetration of the host’s tissues, thus interfering with the body’s ability to ward off infection.
Fungal infections from pathogenic yeasts have become more prominent due to the widespread use of antibiotics and a larger population of people living with compromised immune systems. Antibiotics used to treat other illnesses often eradicate a patient's beneficial gut flora which is needed to keep fungi and yeasts in balance. This results in higher rates of fungal infections after the antibiotic therapy has concluded. As a result, fungal infections are becoming increasingly lethal for immunecompromised patients due to the small number of effective anti-fungal drugs available and the growing resistance to those drugs.
The NanoLogix Solution - Live-threat microorganism detection in 12-16 hours
Current detection times for pathogenic yeasts such as Candida using conventional Petri dish technology take 48-72 hours. With simple to use NanoLogix technology, those wait times can be cut by 75 percent, down to just 12-16 hours. This is approximately 2 hours less than the current and complex method of rapid detection by Flow Cytometry, which can take up to 18 hours for confirmed results.
The advantage is clear. Using NanoLogix BNP technology is more cost-effective and beneficial in hospitals where immunocompromised patients are undergoing treatment, are recovering from other illnesses, and where the likelihood for the spread of fungal infection is high. Faster, live-threat microorganism test results from NanoLogix will reduce the spread of infection and serve to lower mortality rates from such opportunistic and pathogenic yeasts.